Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 8 |
List of Tables | 8 | 1 |
List of Figures | 9 | 1 |
Introduction | 10 | 1 |
Global Markets Direct Report Coverage | 10 | 1 |
Ankylosing Spondylitis (Bekhterev's Disease) Overview | 11 | 1 |
Therapeutics Development | 12 | 1 |
Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) Overview | 12 | 1 |
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics under Development by Companies | 13 | 2 |
Ankylosing Spondylitis (Bekhterev's Disease) Pipeline Products Glance | 15 | 4 |
Late Stage Products | 15 | 1 |
Clinical Stage Products | 16 | 1 |
Early Stage Products | 17 | 1 |
Unknown Stage Products | 18 | 1 |
Ankylosing Spondylitis (Bekhterev's Disease) Products under Development by Companies | 19 | 3 |
Ankylosing Spondylitis (Bekhterev's Disease) Companies Involved in Therapeutics Development | 22 | 25 |
AbbVie Inc | 22 | 1 |
Alteogen Inc. | 23 | 1 |
Amgen Inc. | 24 | 1 |
BIOCAD | 25 | 1 |
Biocon Limited | 26 | 1 |
Bionovis SA | 27 | 1 |
Brickell Biotech, Inc. | 28 | 1 |
Celgene Corporation | 29 | 1 |
Coherus BioSciences, Inc. | 30 | 1 |
Genor BioPharma Co Ltd | 31 | 1 |
Innovent Biologics, Inc. | 32 | 1 |
Johnson &Johnson | 33 | 1 |
Momenta Pharmaceuticals, Inc. | 34 | 1 |
Mycenax Biotech Inc. | 35 | 1 |
NeuClone Pty Ltd | 36 | 1 |
Novartis AG | 37 | 1 |
Oncobiologics, Inc. | 38 | 1 |
Panacea Biotec Limited | 39 | 1 |
Protalix BioTherapeutics, Inc. | 40 | 1 |
Reliance Life Sciences Pvt. Ltd. | 41 | 1 |
Sandoz International GmbH | 42 | 1 |
Shanghai Pharmaceutical Co., Ltd. | 43 | 1 |
Therapeutic Proteins International, LLC | 44 | 1 |
Vitae Pharmaceuticals, Inc. | 45 | 1 |
Xbrane Biopharma AB | 46 | 1 |
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Assessment | 47 | 9 |
Assessment by Monotherapy Products | 47 | 1 |
Assessment by Target | 48 | 2 |
Assessment by Mechanism of Action | 50 | 2 |
Assessment by Route of Administration | 52 | 2 |
Assessment by Molecule Type | 54 | 2 |
Drug Profiles | 56 | 90 |
adalimumab biosimilar Drug Profile | 56 | 2 |
adalimumab biosimilar Drug Profile | 58 | 1 |
adalimumab biosimilar Drug Profile | 59 | 1 |
adalimumab biosimilar Drug Profile | 60 | 1 |
adalimumab biosimilar Drug Profile | 61 | 1 |
adalimumab biosimilar Drug Profile | 62 | 1 |
adalimumab biosimilar Drug Profile | 63 | 2 |
adalimumab biosimilar Drug Profile | 65 | 2 |
adalimumab biosimilar Drug Profile | 67 | 1 |
adalimumab biosimilar Drug Profile | 68 | 1 |
adalimumab biosimilar Drug Profile | 69 | 1 |
adalimumab biosimilar Drug Profile | 70 | 1 |
adalimumab biosimilar Drug Profile | 71 | 1 |
adalimumab biosimilar Drug Profile | 72 | 1 |
apremilast Drug Profile | 73 | 11 |
BBI-6000 Drug Profile | 84 | 2 |
certolizumab pegol biosimilar Drug Profile | 86 | 1 |
DNX-114 Drug Profile | 87 | 1 |
DNX-514 Drug Profile | 88 | 1 |
etanercept biosimilar Drug Profile | 89 | 1 |
etanercept biosimilar Drug Profile | 90 | 2 |
etanercept biosimilar Drug Profile | 92 | 1 |
etanercept biosimilar Drug Profile | 93 | 1 |
etanercept biosimilar Drug Profile | 94 | 1 |
etanercept biosimilar Drug Profile | 95 | 1 |
etanercept biosimilar Drug Profile | 96 | 3 |
etanercept biosimilar Drug Profile | 99 | 1 |
etanercept biosimilar Drug Profile | 100 | 2 |
golimumab Drug Profile | 102 | 8 |
golimumab biosimilar Drug Profile | 110 | 1 |
golimumab biosimilar Drug Profile | 111 | 1 |
infliximab biosimilar Drug Profile | 112 | 1 |
infliximab biosimilar Drug Profile | 113 | 1 |
infliximab biosimilar Drug Profile | 114 | 3 |
infliximab biosimilar Drug Profile | 117 | 1 |
infliximab biosimilar Drug Profile | 118 | 3 |
infliximab biosimilar Drug Profile | 121 | 1 |
infliximab biosimilar Drug Profile | 122 | 1 |
infliximab biosimilar Drug Profile | 123 | 1 |
INV-17 Drug Profile | 124 | 1 |
risankizumab Drug Profile | 125 | 3 |
secukinumab Drug Profile | 128 | 13 |
thalidomide Drug Profile | 141 | 1 |
upadacitinib tartrate Drug Profile | 142 | 2 |
VTP-43742 Drug Profile | 144 | 2 |
Ankylosing Spondylitis (Bekhterev's Disease) Dormant Projects | 146 | 2 |
Ankylosing Spondylitis (Bekhterev's Disease) Discontinued Products | 148 | 1 |
Ankylosing Spondylitis (Bekhterev's Disease) Product Development Milestones | 149 | 13 |
Featured News &Press Releases | 149 | 1 |
Nov 03, 2016: Janssen to Present Data on SIMPONI ARIA (golimumab) at the 2016 American College of Rheumatology Meeting | 149 | 1 |
Oct 31, 2016: Novartis Wins Prestigious Prix Galien Foundation Award, Cosentyx as Best Biotechnology Product | 150 | 1 |
Sep 12, 2016: Innovent IBI303 to Initiate Pivotal Clinical Comparability studies with Adalimumab | 151 | 1 |
Aug 04, 2016: NICE draft guidance recommends new drug for people with ankylosing spondylitis | 151 | 1 |
Jul 17, 2016: SB5, An Adalimumab Biosimilar Referencing Humira, Accepted for Review by European Medicines Agency | 152 | 1 |
Jul 13, 2016: Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases | 153 | 1 |
Jun 28, 2016: Sandoz Canada Regulatory Submission for Subsequent Entry Biologic Etanercept Accepted for Review by Health Canada | 153 | 1 |
Jun 14, 2016: SIMPONI (golimumab) shows long-term treatment persistence and improved quality of life in patients with rheumatic diseases | 154 | 1 |
Jun 08, 2016: Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016 | 155 | 1 |
May 30, 2016: FLIXABI, Biogens Infliximab Biosimilar Referencing Remicade, Approved in the European Union | 156 | 1 |
May 23, 2016: Samsung Bioepis Biologics License Application for SB2 Infliximab Biosimilar Accepted by U.S. Food and Drug Administration | 157 | 1 |
Apr 27, 2016: COSENTYX - first Interleukin-17A inhibitor for psoriatic arthritis and ankylosing spondylitis approved by Health Canada | 158 | 1 |
Apr 01, 2016: FLIXABI, an Infliximab Biosimilar Candidate Referencing Remicade, Receives Positive CHMP Opinion | 158 | 1 |
Apr 01, 2016: Samsung Bioepis Flixabi Infliximab Biosimilar Recommended for Approval in the European Union | 159 | 1 |
Mar 16, 2016: Significantly higher persistence with SIMPONI (golimumab) in patients with rheumatic diseases compared with other subcutaneous TNF-alpha inhibitors, new study reveals | 160 | 2 |
Appendix | 162 | 2 |
Methodology | 162 | 1 |
Coverage | 162 | 1 |
Secondary Research | 162 | 1 |
Primary Research | 162 | 1 |
Expert Panel Validation | 162 | 1 |
Contact Us | 162 | 1 |
Disclaimer | 163 | 1 |